For research use only. Not for therapeutic Use.
MK-8666 Tris（Cat No.:I032404）is a selective small molecule inhibitor that targets the receptor tyrosine kinase AXL, which is implicated in various forms of cancer, particularly those with resistance to conventional therapies. AXL plays a role in tumor progression, metastasis, and immune evasion. MK-8666 Tris is being investigated for its potential to block the signaling pathways associated with AXL, thereby inhibiting tumor growth and improving responses to cancer treatments. It is being explored in preclinical and clinical trials for its application in treating solid tumors and other cancers with AXL overexpression.
| Catalog Number | I032404 |
| CAS Number | 2056254-98-7 |
| Synonyms | MK-8666 tris salt; MK-8666; MK 8666; MK8666 |
| Molecular Formula | C33H42N2O9S |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 2-amino-2-(hydroxymethyl)propane-1,3-diol;(2S,3S,4R)-8-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-9-azatricyclo[4.4.0.02,4]deca-1(10),6,8-triene-3-carboxylic acid |
| InChI | InChI=1S/C29H31NO6S.C4H11NO3/c1-17-10-22(35-8-5-9-37(3,33)34)11-18(2)26(17)20-7-4-6-19(12-20)16-36-25-14-21-13-23-27(24(21)15-30-25)28(23)29(31)32;5-4(1-6,2-7)3-8/h4,6-7,10-12,14-15,23,27-28H,5,8-9,13,16H2,1-3H3,(H,31,32);6-8H,1-3,5H2/t23-,27-,28+;/m1./s1 |
| InChIKey | IMBNJMBRVNORTO-SQMFDTLJSA-N |
| SMILES | CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=NC=C4[C@H]5[C@H]([C@@H]5C(=O)O)CC4=C3)C)OCCCS(=O)(=O)C.C(C(CO)(CO)N)O |
| Reference | 1: Hyde AM, Liu Z, Kosjek B, Tan L, Klapars A, Ashley ER, Zhong YL, Alvizo O, Agard NJ, Liu G, Gu X, Yasuda N, Limanto J, Huffman MA, Tschaen DM. Synthesis of the GPR40 Partial Agonist MK-8666 through a Kinetically Controlled Dynamic Enzymatic Ketone Reduction. Org Lett. 2016 Nov 18;18(22):5888-5891. Epub 2016 Nov 1. PubMed PMID: 27802043. |
